A 76-year-old man with recurrent clostridium difficile associated diarrhea: review of c difficile infection

JAMA

Volumn 301, Issue 9, 2009, Pages 954-962

  Kelly, Ciarán P ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFPODOXIME; CEFTRIAXONE; METRONIDAZOLE; RIFAXIMIN; VANCOMYCIN; ANTIINFECTIVE AGENT; BACTERIAL TOXIN; PROBIOTIC AGENT;

AGED; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; HOSPITAL READMISSION; HUMAN; LOOSE FECES; MALE; PRESCRIPTION; PRIORITY JOURNAL; RECURRENT DISEASE; TREATMENT RESPONSE; URINARY TRACT INFECTION; CLINICAL OBSERVATION; CLINICAL STUDY; DIAGNOSIS; DIARRHEA; HOSPITALIZATION; INTESTINE; MICROBIOLOGY; PATHOGENICITY; PSEUDOMEMBRANOUS COLITIS; REVIEW; RISK FACTOR;

AGED; ANTI-BACTERIAL AGENTS; BACTERIAL TOXINS; CLOSTRIDIUM DIFFICILE; DIARRHEA; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS; INTESTINES; MALE; METRONIDAZOLE; PROBIOTICS; RECURRENCE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; VANCOMYCIN;

EID: 61549093691     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2009.171     Document Type: Article

References (76)

1. Hall IC, O'Toole E. Intestinal flora in new-born infants: with a description of a new pathogenic anaerobe, Bacillus difficilis. AJDC. 1935;49:390-402.
2. Bartlett JG. Antibiotic-associated diarrhea. N Engl J Med. 2002;346(5):334- 339.
3. Dial S, Kezouh A, Dascal A, Barkun A, Suissa S. Patterns of antibiotic use and risk of hospital admission because of Clostridium difficile infection. CMAJ. 2008; 179(8):767-772.
4. Pépin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis. 2005;41(9):1254-1260.
5. Johnson S, Samore MH, Farrow KA, et al. Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals. N Engl J Med. 1999;341(22):1645-1651.
6. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis. 2O07;45(3):302-307.
7. Centers for Disease Control and Prevention (CDC). Severe Clostridium difficile- associated disease in populations previously at low risk. MMWR Morb Mortal Wkly Rep. 2005;54(47):1201-12O5.
8. An and A, Glatt AE. Clostridium difficile infection associated with antineoplastic chemotherapy: a review. Clin Infect Dis. 1993;17(1):109-113.
9. Mylonaki M, Langmead L, Pantes A, Johnson F, Rampton DS. Enteric infection in relapse of inflammatory bowel disease: importance of microbiological examination of stool. Eur J Gastroenterol Hepatol. 2004;16(8):775-778.
10. Nguyen GC, Kaplan GG, Harris ML, Brant SR. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol. 2008;103(6):1443-1450.
11. Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile - assoc iated disease. JAM A. 2005;294(23):2989-2995.
12. Warny M, Kelly CP. Pathogenicity of Clostridium difficile toxins. In: Hecht G, ed. Microbial Pathogenesis and the Intestinal Epithelial Cell. Washington, DC: ASM Press; 2003:503-524.
13. Drudy D, Harnedy N, Fanning S, O'Mahony R, Kyne L. Isolation and characterisation of toxin A-negative, toxin B-positive Clostridium difficile in Dublin, Ireland. Clin Microbiol Infect. 2007;13(3):298-304.
14. Johnson S, Kent SA, O'Leary KJ, et al. Fatal pseudomembranous colitis associated with a variant Clostridium difficile strain not detected by toxin A immunoassay. Ann Intern Med. 2001;135(6):434-438.
15. RieglerM, Sedivy R, Pothoulakis C, et al. Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro. J Clin Invest. 1995;95(5):2004-2011.
16. Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med. 2000; 342(6)390-397.
17. Hirschhorn LR, Trnka Y, Onderdonk A, Lee ML, Piatt R. Epidemiology of community-acquired Clostridium difficile-associated diarrhea. J Infect Dis. 1994; 169(1):127-133.
18. Kyne L, Hamel MB, Polavaram R, Kelly CP. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis. 2O02;34(3):346-353.
19. McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996 to 2003. Emerg Infect Dis. 2006;12(3):409-415.
20. McFarland LV, Mulligan ME, Kwok RY, Stamm WE. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med. 1989;320(4):204-210.
21. Kyne L, Sougioultzis S, McFarland LV, Kelly CP. Underlying disease severity as a major risk factor for nosocomial Clostridium difficile diarrhea. Infect Control Hosp Epidemiol. 2002;23(11):653-659.
22. Pépin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity.CMAJ. 2004;171(5):466-472.
23. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005;353(23):2442-2449.
24. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin genevariant strain of Clostridium difficile. N Engl J Med. 2005;353(23):2433-2441.
25. Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet. 2001;357(9251):189-193.
26. UK National Statistics. Clostridium difficile: number of deaths increase in 2007. http://www.statistics.gov.uk/cci/nugget.asp?id=1735. Accessed January 28,2009.
27. Warny M, Pepin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet. 2005;366(9491):1079-1084.
28. MacCannell DR, Louie TJ, Gregson DB, et al. Molecular analysis of Clostridium difficile PCR ri bo type 027 isolates from Eastern and Western Canada. J Clin Microbiol. 2006;44(6):2147-2152.
29. Bartlett JG, Gerding DN. Clinical recognition and diagnosis of Clostridium difficile infection. Clin Infect Dis. 2008;46(suppl 1):S12-S18.
30. Alfa MJ, Swan B, VanDekerkhove B, Pang P, Harding GK. The diagnosis of Clostridium difficile-associated diarrhea: comparison of triage C difficile panel, EIA for tox A/B and cytotoxin assays. Diagn Microbiol Infect Dis. 2002;43 (4):257-263.
31. Stamper PD, Alcabasa R, Aird D, et al. Comparison of a commercial real-time PCR assay for tcdB detection to a cell culture cytotoxicity assay and toxigenic culture for direct detection of toxin producing Clostridium difficile in clinical samples [published online ahead of print December 10, 2008]. J Clin Microbiol. doi: 10.1128/JCM.01613-08.
32. Issack Ml, ElliottTS. Clostridium difficile carriage after infection. Lancet. 1990; 335(8689):610-611.
33. Owens RC Jr, Donskey CJ, Gaynes RP, Loo VG, Muto CA. Antimicrobial- associated risk factors for Clostridium difficile infection. Clin Infect Dis. 2008; 46(suppl 1):S19-S31.
34. Segarra-Newnham M. Probiotics for Clostridium difficile-associated diarrhea: focus on Lactobacillus rhamnosus GG and Saccharomyces boulardii. Ann Pharmacother. 2007;41(7):1212-1221.
35. Hickson M, D'Souza AL, Muthu N, et al. Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ. 2007;335(7610):80.
36. Vonberg RP, Kuijper EJ, Wilcox MH, etal; European C difficile- Infection Control Group; European Centre for Disease Prevention and Control (ECDC). Infection control measures to limit the spread of Clostridium difficile. Clin Microbiol Infect. 2008;14(suppl 5):2-20.
37. Gerding DN, Muto CA, Owens RC Jr. Measures to control and prevent Clostridium difficile infection. Clin Infect Dis. 2008;46(suppl 1):S43-S49.
38. Centers for Disease Control and Prevention. Understanding Clostridium difficile: A Patient's Guide. http://www.rmei.com/cdadbrochure/ UnderstandingCD-Brochure.pdfPle. Accessed January 15, 2009.
39. Teasley DC, Gerding DN, Olson MM, et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium difficile-associated diarrhoea and colitis. Lancet. 1983;2(8358):1043-1046.
40. Louie T, Gerdsom M, Grimard D, et al. Results of a phase III trial comparing tolevamer, vancomycin and metronidazole in patients with Clostridium difficile-associated diarrhea (CDI). Abstract presented at the 47th Annual Interscience Conference on Antimicrobial Agents and Chermotherapy Meeting; September 17-20, 2007; Chicago, IL.
41. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol. 2002;97(7):1769-1775.
42. Canadian Task Force on the Periodic Health Examination. The periodic health examination. CMAJ. 1979;121(9):1193-1254.
43. Gerding DN, Muto CA, Owens RC Jr. Treatment of Clostridium difficile infection. Clin Infect Dis. 2008;46(suppl 1):S32-S42.
44. Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). Am J Infect Control. 1995;23(2):87-94.
45. Stepan C, Surawicz CM. Treatment strategies for recurrent and refractory Clostridium difficile-associated diarrhea. Expert Rev Gastroenterol Hepatol. 2007; 1(2):295-305.
46. Follmar KE, Condron SA, Turner II, Nathan JD, Ludwig KA. Treatment of metronidazole-refractory Clostridium difficile enteritis with vancomycin. Surg Infect (Larchmt). 2008;9(2):195-200.
47. Jaber MR, Olafsson S, Fung WL, Reeves ME. Clinical review of the management of fulminant Clostridium difficile infection. Am J Gastroenterol. 2008; 103(12)3195-3203, quiz 3204.
48. Greenstein AJ, Byrn JC, Zhang LP, Swedish KA, Jahn AE, Divino CM. Risk factors for the development of fulminant Clostridium difficile colitis. Surgery. 2008; 143(5):623-629.
49. Triadafilopoulos G, Hailstone AE. Acute abdomen as the first presentation of pseudomembranous colitis. GastroenteroIogy. 1991;101 (3):685-691.
50. Salcedo J, KeatesS, PothoulakisC, et al. Intravenous immunoglobulin therapy for severe Clostridium difficile colitis. Gut. 1997;41(3):366-370.
51. Juang P, Skledar SJ, Zgheib NK, et al. Clinical outcomes of intravenous immune globulin in severe Clostridium difficile-associated diarrhea. Am J Infect Control. 2007;35(2):131-137.
52. Grundfest-BroniatowskiS, QuaderM, Alexander F, Walsh RM, Lavery I, Milsom J. Clostridium difficile colitis in the critically ill. Dis Colon Rectum. 1996;39 (6):619-623.
53. Viscidi R, Laughon BE, Yolken R, et al. Serum antibody response to toxins A and B of Clostridium difficile. J Infect Dis. 1983;148(1):93-100.
54. Kyne L, Kelly CP. Recurrent Clostridium difficile diarrhoea. Gut. 2001; 49(1):152-153.
55. Aslam S, Hamill RJ, Musher DM. Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect Dis. 2005;5(9): 549-557.
56. McFarland LV, Surawicz CM, Green berg RN, et al. A randomized placebocontrolled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA. 1994;271(24):1913-1918.
57. Wilcox MH, Fawley WN, Settle CD, Davidson A. Recurrence of symptoms in Clostridium difficile infection-relapse or reinfection? J Hosp Infect. 1998; 38(2):93-100.
58. Tedesco FJ, Gordon D, Fortson WC. Approach to patients with multiple relapses of antibiotic - associated pseudomembranous colitis. Am J Gastroenterol. 1985; 80(11):867-868.
59. Surawicz CM, McFarland LV, Green berg RN, et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis. 2000;31(4):1012- 1017.
60. Aas J, Gessert CE, Bakken JS. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis. 2003;36(5):580-585.
61. Seal D, Bordello SP, Barclay F, Welch A, Piper M, Bonnycastle M. Treatment of relapsing Clostridium difficile diarrhoea by administration of a non-toxigenic strain.Eur J Clin Microbiol. 1987;6(1):51-53.
62. Johnson S, Schriever C, Galang M, Kelly CP, Gerding DN. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis. 2007;44(6):846-848.
63. Kreutzer EW, Milligan FD. Treatment of antibiotic-associated pseudomembranous colitis with cholestyramine resin. Johns Hopkins Med J. 1978;143 (3):67-72.
64. Leung DY, Kelly CP, Boguniewicz M, PothoulakisC, LaMontJT, Flores A. Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. 7 Pediatr. 1991;118(4 pt 1):633-637.
65. Wilcox MH. Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea. J Antimicrob Chemother. 2004; 53(5):882-884.
66. Kotloff KL, Wasserman SS, Losonsky GA, et al. Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults. Infect Immun. 2001;69(2):988-995.
67. Sougioultzis S, Kyne L, Drudy D, et al. Clostridium difficile toxoid vaccine in recurrent C difficile-associated diarrhea. GastroenteroIogy. 2005;128(3):764-770.
68. Kyne L, Kelly C. Prospects for a vaccine for Clostridium difficile. Bio Drugs. 1998;10(3):173-181.
69. Aboudola S, Kotloff KL, Kyne L, et al. Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A. Infect Immun. 2003;71(3): 1608-1610.
70. Giannasca PJ, Warny M. Active and passive immunization against Clostridium difficile diarrhea and colitis. Vaccine. 2004;22(7):848-856.
71. Babcock GJ, Broering TJ, Hernandez HJ, et al. Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect Immun. 2006;74(11):6339-6347.
72. Czerucka D, Piche T, Rampal P. Yeast as probiotics: Saccharomyces boulardii. Aliment Pharmacol Ther. 2007;26(6):767-778.
73. Izadnia F, Wong CT, Kocoshis SA. Brewer's yeast and Saccharomyces boulardii both attenuate Clostridium difficile-induced colonic secretion in the rat. Dig Dis Sci. 1998;43(9):2055-2060.
74. Qamar A, Aboudola S, Warny M, et al. Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in mice. Infect Immun. 2001;69(4):2762-2765.
75. Pothoulakis C, Kelly CP, Joshi MA, et al. Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum. Gastroenterology. 1993;104(4):1108-1115.
76. Chen X, Kokkotou EG, Mustafa N, et a\. Saccharomyces boulardii inhibits ERK1/2 mitogen - activated protein kinase activation both in vitro and in vivo and protects against Clostridium difficile toxin A-induced enteritis. J Biol Chem. 2006; 281(34):24449-24454.